RHJ Begent

705 total citations
18 papers, 564 citations indexed

About

RHJ Begent is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, RHJ Begent has authored 18 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in RHJ Begent's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Glycosylation and Glycoproteins Research (3 papers). RHJ Begent is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Glycosylation and Glycoproteins Research (3 papers). RHJ Begent collaborates with scholars based in United Kingdom and United States. RHJ Begent's co-authors include R Boden, RB Pedley, R.G. Dale, F Searle, JA Ledermann, Damian Marshall, K. D. Bagshawe, K D Bagshawe, RG Melton and DJ King and has published in prestigious journals such as British Journal of Cancer.

In The Last Decade

RHJ Begent

18 papers receiving 539 citations

Peers

Countries citing papers authored by RHJ Begent

Since Specialization

Citations

This map shows the geographic impact of RHJ Begent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RHJ Begent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RHJ Begent more than expected).

Fields of papers citing papers by RHJ Begent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RHJ Begent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RHJ Begent. The network helps show where RHJ Begent may publish in the future.

Co-authorship network of co-authors of RHJ Begent

This figure shows the co-authorship network connecting the top 25 collaborators of RHJ Begent. A scholar is included among the top collaborators of RHJ Begent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RHJ Begent. RHJ Begent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle 1998 ·British Journal of Cancer ·(unknown), DJ King, RB Pedley, (unknown), R Boden, L Chaplin, (unknown), RHJ Begent	4
2	Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody 1996 ·British Journal of Cancer ·Damian Marshall, RB Pedley, (unknown), R Boden, RG Melton, RHJ Begent	48
3	Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification 1996 ·British Journal of Cancer ·Cristina Delgado, RB Pedley, Ángel Herráez, R Boden, (unknown), (unknown), Kerry Chester, Derek Fisher, RHJ Begent, G. E. Francis	53
4	Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments 1996 ·British Journal of Cancer ·(unknown), DJ King, L Chaplin, (unknown), RB Pedley, Angela Mountain, (unknown), RHJ Begent	44
5	Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody 1995 ·British Journal of Cancer ·Damian Marshall, RB Pedley, RG Melton, (unknown), R Boden, RHJ Begent	31
6	Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model 1994 ·British Journal of Cancer ·Damian Marshall, RB Pedley, (unknown), R Boden, RHJ Begent	25
7	Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA) – implications for targeted therapy 1994 ·British Journal of Cancer ·(unknown), (unknown), RB Pedley, RHJ Begent	12
8	The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody 1994 ·British Journal of Cancer ·RB Pedley, (unknown), R Boden, RHJ Begent, Alison Turner, (unknown), DJ King	46
9	Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model 1993 ·British Journal of Cancer ·(unknown), (unknown), R Boden, R.G. Dale, RHJ Begent	53
10	Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy 1992 ·British Journal of Cancer ·(unknown), J. E. Boultbee, Ruth E. Langley, E.S. Newlands, RHJ Begent, K. D. Bagshawe	23
11	Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model 1991 ·British Journal of Cancer ·Tom Hennigan, RHJ Begent, T G Allen-Mersh	20
12	Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy 1990 ·British Journal of Cancer ·(unknown), ES Newlands, (unknown), RHJ Begent, (unknown), (unknown), K. D. Bagshawe	38
13	Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry 1990 ·British Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), RHJ Begent, K. D. Bagshawe, John L. Humm, F Searle	9
14	Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer 1989 ·British Journal of Cancer ·RHJ Begent, JA Ledermann, (unknown), K D Bagshawe, (unknown), F Searle, (unknown), Tomáš Adam, R.G. Dale, (unknown)	50
15	The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy 1989 ·British Journal of Cancer ·S. M. Crawford, ES Newlands, RHJ Begent, (unknown), K. D. Bagshawe	9
16	Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A 1988 ·British Journal of Cancer ·JA Ledermann, RHJ Begent, K D Bagshawe, (unknown), F Searle, (unknown), (unknown), R.G. Dale	65
17	Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits 1988 ·British Journal of Cancer ·JA Ledermann, RHJ Begent, K. D. Bagshawe	17
18	The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma 1987 ·British Journal of Cancer ·RHJ Begent, K D Bagshawe, (unknown), F Searle	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact